Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NMT Medical starts US trial for PFO(patent foramen ovale)/migraine therapy STARFlex implant:

This article was originally published in Clinica

Executive Summary

NMT Medical has begun a US trial to test its heart repair implant as a treatment for migraine headaches. The MIST II trial, which has begun patient enrolment, will assess the firm's STARFlex device, which is used to close a patent foramen ovale (PFO), a cardiac defect that has been linked an increased risk of migraine, recurrent stroke and transient ischaemic attacks. It will involve 600 patients, with enrolment scheduled for completion by the end of this year. Patients will be followed-up over a one-year period. The Boston, Massachusetts firm has already completed enrolment in a UK PFO/migraine study, MIST, results from which are scheduled for release in late March or early April 2006.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050669

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel